PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer
The International Journal of Biological Markers · 2026-06 · 41
DOI: 10.1177/03936155261451883 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Biological Markers, online erschienen am 03.07.2026. Verfasst von Katie-Rose Cawthorne und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Institute of Clinical Sciences, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Phosphofructokinase-1, Type C. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charitable funds of Departments of Cellular Pathology of the Liverpool University Hospitals NHS Foundation Trust.
Abstract (Originalsprache)
Background
Phosphofructokinase-platelet (PFKP) is a rate-limiting enzyme in glycolysis. PFKP is highly expressed across many cancer types including breast cancer.
Purpose
To assess the extent to which PFKP can be a prognostic indicator in breast cancer and its ability to predict treatment response. To further understanding of the interaction between PFKP and key signaling pathways in cancer progression, the immune system, and epigenetics.
Methods
Using online platforms (Kaplan–Meier plotter, receiver operating characteristic curve plotter, cBioPortal, and Tumor-Immune System Interaction Database (TISIDB)), a bioinformatic analysis was conducted to establish the prognostic and predictive effects related to PFKP expression in breast cancer. A network analysis was performed using the Oncomine platform where signaling, epigenetic, and immune regulation pathways were investigated.
Results
PFKP had a poor prognostic effect in breast cancer, demonstrated at both the RNA and protein levels. This effect was prominent in advanced breast cancers. PFKP appeared to recruit hallmark cancer pathways early in the progression lifecycle, from ductal carcinoma in situ to advanced cancer. PFKP was a biomarker of resistance to chemotherapy in the short-term for luminal A breast cancer and triple-negative breast cancer, and of sensitivity to endocrine therapy over the long term for luminal B breast cancer. PFKP interacts with immune system components such tumor-infiltrating lymphocytes, chemokines, and immunomodulators.
Conclusions
PFKP is overexpressed in breast cancer and has a poor prognostic effect, particularly in aggressive subtypes and advanced disease. It plays a key role in hallmark cancer pathways and interacts with the immune system in ways that could be harnessed for future therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Institute of Clinical Sciences, University of Liverpool, Liverpool, UK.
- Department of Cellular Pathology, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
ORCID-Profile: Katie-Rose Cawthorne, Vijay Sharma
Förderung
- Charitable funds of Departments of Cellular Pathology of the Liverpool University Hospitals NHS Foundation Trust
Zitieren
APA
Cawthorne, K. R., Heath, A., & Sharma, V. (2026). PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer. The International Journal of Biological Markers, 41. https://doi.org/10.1177/03936155261451883
Vancouver
Cawthorne KR, Heath A, Sharma V. PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer. The International Journal of Biological Markers. 2026;41. doi:10.1177/03936155261451883
BibTeX
@article{Cawthorne2026,
author = {Cawthorne, Katie-Rose and Heath, Alistair and Sharma, Vijay},
title = {PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer},
journal = {The International Journal of Biological Markers},
year = {2026},
volume = {41},
doi = {10.1177/03936155261451883}
}
EUVIMED